https://www.prnewswire.com/news-releases/durect-corporation-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference-302366991.html
DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President and Chief Executive Officer, will present at the Oppenheimer...
healthcare life sciences
https://www.news-medical.net/news/20090819/Orient-Pharma-granted-commercialization-rights-for-a-drug-candidate-by-DURECT.aspx
Orient Pharma granted commercialization rights for a drug candidate by DURECT
Jun 20, 2019 - DURECT Corporation today announced that it has signed a development and license agreement with Orient Pharma Co., Ltd., a diversified multinational...
for aorientpharmagrantedcommercialization
https://www.businesswire.com/news/home/20250729171780/en/Shareholder-Alert-The-Ademi-Firm-Investigates-Whether-DURECT-Corporation-Is-Obtaining-a-Fair-Price-for-Its-Public-Shareholders
Shareholder Alert: The Ademi Firm Investigates Whether DURECT Corporation Is Obtaining a Fair Price...
The Ademi Firm is investigating DURECT (NYSE: DRRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Bausch Health...
https://www.prnewswire.com/news-releases/durect-announces-patient-dosing-in-phase-2a-trial-of-dur-928-in-primary-sclerosing-cholangitis-psc-300603773.html
DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Primary Sclerosing Cholangitis (PSC)
/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient dosing in a Phase 2a clinical trial of DUR-928 in patients with...